Using therapeutic strategies targeting the IL-17A pathway and drugs that prevent the progression from MASLD to MASH, such as polyunsaturated phosphatidylcholine (PPC) and 3’,3’-diidolylmethane (DIM), restored the immune balance Th17/Treg reducing liver inflammation and the hepatic steatosis (Figure 2G) (122, 123). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.